Glucosamine and chondroitin are not the beginning and end of joint health. Collagen synthesis is a biochemical process with six specific nutrient dependencies. Get any one of them wrong and the scaffold fails — regardless of how much glucosamine you take. Here is what the process actually requires.
The joint supplement market is enormous and largely built on a misunderstanding. Glucosamine and chondroitin — the most widely sold joint supplements globally — provide substrate for cartilage proteoglycan synthesis. That’s the theory. In trials they haven’t delivered meaningful relief for knee pain (more below), and the theory addresses only one layer of a much more complex structural problem. It bypasses the foundational process: collagen synthesis.
Collagen is the most abundant protein in the human body. It makes up approximately 30% of total protein mass and is the primary structural component of tendons, ligaments, cartilage, bone matrix, skin, blood vessel walls, and the cornea. Every connective tissue in the body — every joint, every tendon, every fascial layer — depends on the quality of its collagen matrix. And collagen synthesis is a nutrient-dependent biochemical process with multiple specific requirements that are rarely assessed and even more rarely supplemented correctly.
Collagen synthesis begins with the transcription of collagen genes (COL1A1, COL1A2 for type I collagen — the most abundant) in fibroblasts. The resulting alpha chains are synthesised on ribosomes and undergo hydroxylation of proline and lysine residues — a step that requires vitamin C (ascorbic acid) as an essential cofactor for the enzymes prolyl hydroxylase and lysyl hydroxylase. Without adequate vitamin C, hydroxylation fails, and the resulting collagen chains cannot form the triple helix structure. This is the molecular basis of scurvy.
The triple helix (procollagen) is assembled from three alpha chains, packaged into secretory vesicles, and exported to the extracellular matrix. There, specific peptidase enzymes cleave propeptides, and lysyl oxidase — a copper-dependent enzyme — cross-links the collagen fibrils, giving the matrix its tensile strength. Without copper, cross-linking fails and the collagen matrix is structurally weak even when synthesis is adequate.
Simultaneously, zinc is required as a cofactor for matrix metalloproteinases (MMPs) that remodel the existing collagen matrix, and for the synthesis of procollagen peptidase. Silicon stimulates collagen type I synthesis via upregulation of COL1A1 gene expression. Glycine and proline are the dominant amino acids in collagen (Gly-X-Y repeat structure) and must be available in abundance for synthesis to proceed at full rate.
The extracellular matrix (ECM) is the structural scaffold in which cells live. It is not inert packaging — it is a dynamic, bioactive environment that regulates cell behaviour, tissue repair, inflammation, and growth factor signalling. Collagen provides the tensile framework, but several other structural molecules are equally important.
Proteoglycans are the molecules that give cartilage its compressive resistance — they attract and retain water, creating the hydraulic cushion that allows joints to absorb load. They consist of a protein core with attached glycosaminoglycan (GAG) chains. The most clinically relevant GAGs are hyaluronic acid, chondroitin sulphate, keratan sulphate, and heparan sulphate.
Hyaluronic acid is the primary GAG in synovial fluid — the lubricating fluid in joints. It is also found in the vitreous humour of the eye, the dermis of the skin, and the umbilical cord. Its exceptional water-binding capacity (one molecule of HA can bind up to 1,000 times its weight in water) explains why its decline with age contributes to dry eyes, skin changes, and reduced joint lubrication. Sulphate (from sulphur-containing amino acids — methionine, cysteine, taurine) is required for GAG sulphation, which is essential for their function.
Where collagen provides tensile strength (resistance to pulling), elastin provides elasticity (the ability to return to shape after deformation). Elastin is predominantly synthesised during foetal development and early childhood — adult elastin synthesis is minimal. This is why sun-damaged, aged, or inflamed skin loses elasticity irreversibly. Copper (via lysyl oxidase) is required for elastin cross-linking just as it is for collagen. Vitamin C also supports elastin stability.
Fibronectin is the ECM protein primarily responsible for cell adhesion, migration, and wound healing. It forms a provisional matrix at injury sites and guides cellular repair processes. Laminin is the primary structural component of basement membranes — the specialised ECM that underlies epithelial and endothelial cells throughout the body, including the gut epithelium. Poor laminin integrity contributes to epithelial fragility and barrier compromise.
Glucosamine is a substrate for glycosaminoglycan synthesis — specifically for the production of chondroitin sulphate, keratan sulphate, and hyaluronic acid. It provides the raw material for proteoglycan production in cartilage. That’s the biochemistry. The trials are less kind. In the GAIT trial (1,583 people with knee osteoarthritis, NEJM 2006), neither glucosamine nor chondroitin, alone or together, relieved knee pain better than placebo; the anti-inflammatory drug celecoxib did. An exploratory look at the smaller group with moderate-to-severe pain favoured the combination, and the authors said that needed confirming (Clegg 2006). It wasn’t confirmed: a network meta-analysis of the large trials found no clinically relevant effect on pain or joint space, and industry-funded trials showed bigger effects than independent ones (Wandel 2010). NICE’s osteoarthritis guideline says “do not offer glucosamine” (NG226, recommendation 1.4.6). Grade: strong evidence of no meaningful benefit. The full comparison is in the knees edition of “I’m Not Getting Any Younger”.
So the substrate argument for glucosamine is plausible on paper and hasn’t held up in people. It also never addressed the upstream collagen synthesis process, the cross-linking requirement for structural integrity, or the specific nutrient shortfalls that impair ECM quality, which is what the rest of this article is about.
Collagen hydrolysate (hydrolysed collagen peptides) looks somewhat better, but the evidence is thin. A meta-analysis of placebo-controlled trials found lower total osteoarthritis symptom scores and lower pain on a visual scale with collagen, but no significant difference on the pain or function subscores of the main osteoarthritis questionnaire (García-Coronado 2019). Grade: mixed. Collagen hydrolysate does supply glycine and proline directly, and some collagen dipeptides are absorbed intact; whether they reach cartilage and change it in people is still mechanistic.
Collagen synthesis does not happen in a hormonal vacuum. Oestrogen upregulates COL1A1 gene expression — this is why perimenopausal and postmenopausal women experience accelerated collagen loss (estimated at 30% of skin collagen in the first 5 years after menopause, paralleled by similar losses in other connective tissues). Testosterone supports connective tissue anabolism in men. Growth hormone and IGF-1 both stimulate collagen synthesis. Cortisol — particularly chronic cortisol excess — is directly anti-anabolic to connective tissue and increases MMP-mediated ECM degradation.
Chronic inflammation drives MMP overexpression, degrading the ECM faster than it can be rebuilt. This is why systemic inflammatory conditions — rheumatoid arthritis, inflammatory bowel disease, obesity-driven inflammation — produce connective tissue destruction that goes far beyond the joints themselves. The testing picture therefore extends well beyond the connective tissue supplements: DUTCH for hormonal context, hsCRP and NLR for inflammatory load, GI-MAP for gut-driven systemic inflammation.
Connective tissue quality is a reflection of the entire hormonal, nutritional, and inflammatory environment over time. A joint supplement cannot overcome oestrogen deficiency, chronic cortisol excess, systemic inflammation, and inadequate protein intake simultaneously. The supplement fills a gap. The testing tells you which gap.
Blood chemistry: Zinc and copper are the most directly relevant markers. Also vitamin C (rarely tested but available), alkaline phosphatase (ALP — low ALP can indicate zinc insufficiency; bone ALP fraction reflects bone collagen turnover). Ferritin (iron is a cofactor for prolyl hydroxylase alongside vitamin C). hsCRP and NLR for inflammatory MMP activation. DUTCH: Oestrogen levels and metabolism (low oestrogen = accelerated collagen loss in women), cortisol metabolites (high metabolised cortisol = catabolic ECM environment), DHEA-S (anabolic-catabolic balance). Metabolomix+ OAT: Hydroxyproline on amino acid profile indicates collagen turnover rate. Vitamin C functional status can be inferred from oxidative stress markers. Copper functional status impacts a range of OAT markers. Urine hydroxyproline: A specific marker of collagen breakdown — not on standard panels but available as a standalone test when detailed collagen turnover assessment is needed.
The right testing tells you whether your joint symptoms are driven by nutrient insufficiency, hormonal decline, chronic inflammation, or all three. Ask the DH Concierge which tests are most relevant to your presentation.
Ask the Concierge → Book a free 20-minute call